ACR had a great day with first Gx FDA approval which is the re-bagded Axiron drug so assume a lot of the work done years ago could have been leveraged.
Its a credit to CEO, Scientific/Technical and Regulatory staff, I still think Dobinson and Board are a liability as they are stale apart from ST position (IMO).
With the competition in generic drug markets and ACR's royalty/profit share model I think we need 6-8 approvals before cash burn to deliver an FDA approval for a wider portfolio is covered.
ACR had a great day with first Gx FDA approval which is the...
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
